



## UCB's General Meeting of Shareholders 2022

- For financial year 2021: Gross dividend of € 1.30 per share (+ 2.36%), payable 3 May 2022
- All agenda items put to vote approved
- The message of Jean-Christophe Tellier, CEO of UCB is available on UCB's global corporate website

**Brussels (Belgium), 28 April 2022 – 18:00 (CEST) (regulated information)** – Today, UCB held its Annual General Meeting of Shareholders (AGM) together with an Extraordinary General Meeting (EGM). The company offered the choice to UCB shareholders to either participate in-person or to cast their vote by proxy and follow the meeting online. At the AGM 147 925 550 shares (77,83% of shares entitled to vote) were represented.

The message of Mr. Jean-Christophe Tellier, Chief Executive Officer of UCB, published at the occasion of this general meeting, is available on the [UCB website](#).

During his speech, Mr. Tellier commented: "2021 was a very strong year, and 2022 is shaping up into a key transition year ... Our continued strong financial performances coupled with impressive clinical milestone achievements and strategic partnerships have provided us the building blocks we need to lead us to our 2025 guidance."

Jean-Christophe Tellier also added: "Looking at UCB today, we have built solid foundations, allowing us to focus on the execution of our strategy in the coming years. We are therefore convinced we can live our ambition and commitment to delivering patient value now and into the future."

The AGM approved for the fiscal year 2021 the payment of a gross dividend of € 1.30 per share (net dividend of € 0.91 per share) compared to € 1.27 per share for 2020 (net € 0.889). The ex-dividend date is 29 April 2022, the dividend (coupon no. 25) will be payable as of 3 May 2022.

During the AGM, several renewals of members of the Board composition were approved. The AGM renewed the mandates of Mrs. Kay Davies as independent director for a term of 4 years and Mr. Jean-Christophe Tellier and Mr. Cédric Rijckevorsel as directors for a term of 4 years. Mrs. Kay Davies is chairing the Scientific Committee of the Board and is bringing a unique scientific contribution at the level of the Board.

For the curriculum vitae of the Board members, please visit the UCB website:  
<https://www.ucb.com/investors/UCB-governance>.

All other agenda items put to vote at the AGM and of the EGM were approved by the shareholders. More information including details of the votes will be available soon [on the corporate website](#).





The Integrated Annual Report 2021 of UCB can be downloaded on UCB's website at <https://www.ucb.com/investors/Download-center> or is available on the online portal at <https://reports.ucb.com/>.

The financial results for the first half year 2022 will be published on 28 July 2022.

Next year's General Meeting will be held on 27 April 2023.

**For further information**, contact UCB:

#### **Investor Relations**

Antje Witte  
Investor Relations, UCB  
T +32.2.559.9414  
[antje.witte@ucb.com](mailto:antje.witte@ucb.com)

#### **Global Communications**

Laurent Schots  
Media Relations, UCB  
T+32.2.559.9264  
[Laurent.schots@ucb.com](mailto:Laurent.schots@ucb.com)

#### **About UCB**

UCB, Brussels, Belgium ([www.ucb.com](http://www.ucb.com)) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 600 people in nearly 40 countries, the company generated revenue of € 5.8 billion in 2021. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB\_news

#### **Forward looking statements**

This press release may contain forward-looking statements including, without limitation, statements containing the words "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "continue" and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to differ materially from those that may be expressed or implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: the global spread and impact of COVID-19, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring and retention of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, will progress to product approval or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB' efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could





# UCB News

discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB's products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB's data and systems.

Given these uncertainties, you should not place undue reliance on any of such forward-looking statements. There can be no guarantee that the investigational or approved products potentially described in this press release will be submitted or approved for sale or for any additional indications or labelling in any market, or at any particular time, nor can there be any guarantee that such products will be or will continue to be commercially successful in the future.

UCB is providing this information, including forward-looking statements, only as of the date of this press release and it does not reflect any potential impact from the evolving COVID-19 pandemic, unless indicated otherwise. UCB is following the worldwide developments diligently to assess the financial significance of this pandemic to UCB. UCB expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.

